Ethan M Basch

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 7:903-9. 2006
  2. ncbi Use of information resources by patients with cancer and their companions
    Ethan M Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:2476-83. 2004
  3. ncbi Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes
    Ethan Basch
    Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10065, USA
    J Natl Cancer Inst 101:1624-32. 2009
  4. ncbi Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, and the Office of the Physician in Chief, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5374-80. 2007
  5. ncbi Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities
    Ethan Basch
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Med Inform Assoc 14:264-8. 2007
  6. ncbi Electronic toxicity monitoring and patient-reported outcomes
    Ethan M Basch
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer J 17:231-4. 2011
  7. ncbi Patient online self-reporting of toxicity symptoms during chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, New York, NY 10021, USA
    J Clin Oncol 23:3552-61. 2005
  8. ncbi Physician visits prior to treatment for clinically localized prostate cancer
    Thomas L Jang
    Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York, USA
    Arch Intern Med 170:440-50. 2010
  9. ncbi A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
    Mario E Lacouture
    Dermatology Service, Rockefeller Outpatient Pavilion, Memorial Sloan Kettering 53rd Street, 160 East 53rd Street, New York, NY 10022, USA
    Support Care Cancer 18:509-22. 2010
  10. ncbi The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pain Med 11:337-46. 2010

Detail Information

Publications20

  1. ncbi Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 7:903-9. 2006
    ..We aimed to compare the reporting of symptom severity reported by patients and clinicians...
  2. ncbi Use of information resources by patients with cancer and their companions
    Ethan M Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:2476-83. 2004
    ..It is not clear as to whether patients and their companions differ in their patterns of content seeking...
  3. ncbi Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes
    Ethan Basch
    Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10065, USA
    J Natl Cancer Inst 101:1624-32. 2009
    ..Patient self-reporting has been proposed as an additional data source, but the implications of such a shift are not understood...
  4. ncbi Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, and the Office of the Physician in Chief, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5374-80. 2007
    ..In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly...
  5. ncbi Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities
    Ethan Basch
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Med Inform Assoc 14:264-8. 2007
    ..Ongoing multi-center research will evaluate the impact of this approach on clinical and administrative outcomes...
  6. ncbi Electronic toxicity monitoring and patient-reported outcomes
    Ethan M Basch
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer J 17:231-4. 2011
    ..The validity, usability, and scalability of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events prototype are currently being examined in academic and community-based settings...
  7. ncbi Patient online self-reporting of toxicity symptoms during chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, New York, NY 10021, USA
    J Clin Oncol 23:3552-61. 2005
    ..Currently, clinicians collect symptom information via complex and often inefficient mechanisms, but there is growing interest in collecting outcome information directly from patients...
  8. ncbi Physician visits prior to treatment for clinically localized prostate cancer
    Thomas L Jang
    Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York, USA
    Arch Intern Med 170:440-50. 2010
    ..We evaluated how visits to specialists and primary care physicians (PCPs) by men with localized prostate cancer are related to treatment choice...
  9. ncbi A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
    Mario E Lacouture
    Dermatology Service, Rockefeller Outpatient Pavilion, Memorial Sloan Kettering 53rd Street, 160 East 53rd Street, New York, NY 10022, USA
    Support Care Cancer 18:509-22. 2010
    ..We believe a class-specific grading scale is needed to help standardize assessment and improve reporting of EGFRI-associated dermatologic AEs...
  10. ncbi The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations
    Thomas M Atkinson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pain Med 11:337-46. 2010
    ..When finalized, it may provide a blueprint for evaluations of PRO measures that can be considered by sponsors and investigators involved in PRO research and drug registration trials...
  11. ncbi Against diagnosis
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Intern Med 149:200-3. 2008
    ..The authors compare and contrast the diagnostic and risk prediction approaches and attempt to identify the types of medical problem to which each is best suited...
  12. ncbi Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  13. ncbi Targeted drugs for metastatic renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Lancet 370:2071-3. 2007
  14. ncbi Validation study of a web-based assessment of functional recovery after radical prostatectomy
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Health Outcomes Group Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Health Qual Life Outcomes 8:82. 2010
    ..Logistical problems associated with using paper questionnaire limit their use in the clinic. We have implemented a web-interface ("STAR") for patient-reported outcomes after radical prostatectomy...
  15. ncbi Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Genitourin Cancer 7:51-7. 2009
    ..This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC)...
  16. ncbi American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer
    Ethan M Basch
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:5313-8. 2007
    ..The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer...
  17. ncbi A prospective study of the feasibility and acceptability of a Web-based, electronic patient-reported outcome system in assessing patient recovery after major gynecologic cancer surgery
    Vaagn Andikyan
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 127:273-7. 2012
    ..The purposes of this study are to evaluate the feasibility of capturing patient-reported outcomes (PROs) electronically and to identify the most common distressing symptoms in women recovering from major gynecologic cancer surgery...
  18. ncbi Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer
    Justin E Bekelman
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 69:1456-66. 2007
    ..S. men...
  19. ncbi Safety assurances for dietary supplements policy issues and new research paradigms
    Ethan M Basch
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Herb Pharmacother 5:3-15. 2005
    ..We discuss research and educational paradigms within this context which make use of existing surveillance mechanisms to more efficiently identify agents of particular concern. Specific examples are given...
  20. ncbi An evidence-based systemic review Echinacea E. angustifolia DC, E. pallida, E. purpurea by the Natural Standard Research Collaboration
    Ethan Basch
    Memorial Sloan Kettering Cancer Center, NY, USA
    J Herb Pharmacother 5:57-88. 2005